
EyePoint Inc
EYPTHealthcare|Biotechnology|USA
$14.72
-0.12 (-0.81%)
Tangible Book
$2.76
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
1.98,
38.85,
301.69,
630.64,
913.5
],
"ebit_estimate": [
-330.99,
-321.84,
-199.53,
-159.62,
153.35
],
"ebitda_estimate": [
-357.34,
-25.6,
30.28,
null,
null
],
"net_income_estimate": [
-317.05,
-313.34,
-154.63,
-148.04,
159.33
],
"per_share_eps_estimate": [
-3.51,
-3.01,
-1.53,
-1.29,
1.25
],
"eps_nri_estimate": [
-3.55,
-3.06,
-1.43,
0.39,
2.49
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
2.99,
2.84,
9.23,
null,
null
],
"pretax_income_estimate": [
-317.08,
-313.34,
-146.74,
-135.79,
180.03
],
"operating_cash_flow_per_share_estimate": [
-2.25,
-0.48,
2.92,
null,
null
],
"roa_estimate": [
-81.4,
-22.5,
17.7,
null,
null
],
"roe_estimate": [
-125.98,
-113.33,
-2.32,
null,
null
],
"gross_margin_estimate": [
28.55,
86.5,
84.33,
84.5,
85
],
"operating_cash_flow_estimate": [
-193.5,
-41.28,
251.12,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
11.8
],
"long_term_growth_rate_mean": 26.04,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 24.65,
"future_eps_nri_estimate_growth": 26.04,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 30.9,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 64.74,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
0.42,
0.34,
0.33,
0.6,
0.6,
0.6,
0.6
],
"ebit_estimate": [
-68.86,
-66.02,
-71,
-84.26,
-92.89,
-86.54,
-88.39
],
"ebitda_estimate": [
0.03,
-10.1,
-17.8,
null,
null,
null,
null
],
"net_income_estimate": [
-80.7,
-74.75,
-77.06,
-82.62,
-91.53,
-85.52,
-87.64
],
"per_share_eps_estimate": [
-0.94,
-0.8,
-0.8,
-0.88,
-0.97,
-0.9,
-0.84
],
"eps_nri_estimate": [
-0.95,
-0.82,
-0.82,
-0.88,
-0.97,
-0.9,
-0.84
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-80.7,
-74.75,
-77.05,
-82.62,
-91.53,
-85.52,
-87.64
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
-157.53,
-180.95,
-211.71,
null,
null,
null,
null
],
"gross_margin_estimate": [
93,
93,
-97,
93,
93,
93,
93
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 26.04,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 24.65,
"future_eps_nri_estimate_growth": 26.04,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 30.9,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 64.74,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}